Palbociclib - Latest Advances

Senescence-Primed Ferroptosis Enabled by a Metal-Organic Framework Nanoplatform for Enhanced Cancer Therapy.

Journal: ACS nano

Published: December 08, 2025

Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.

Journal: Journal of medical economics

Published: December 08, 2025

Selective CDK6 Degradation via the KLHDC2 E3 Ubiquitin Ligase.

Journal: Journal of medicinal chemistry

Published: December 02, 2025

Redox-responsive palbociclib-loaded self-assembled protein nanoparticles in breast cancer therapy-quality by design approach and efficacy assessment in 2D and 3D in vitro culture systems.

Journal: Pharmaceutical development and technology

Published: December 01, 2025

Glycogen-Linked TPGS Nanomicelles for Hypoxia-Responsive PD-L1 Targeting and Molecular Imaging of Breast Tumor.

Journal: ACS biomaterials science & engineering

Published: November 30, 2025

Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.

Journal: Journal of managed care & specialty pharmacy

Published: November 26, 2025

Cost-effectiveness analysis of ribociclib versus palbociclib as a first line therapy in HR+/HER2- advanced breast cancer: evidence from the Chilean Public Health system.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: November 21, 2025

How to prevent and treat cardiovascular diseases in people living with breast cancer? Recent advances.

Journal: Kardiologia polska

Published: November 04, 2025

Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS.

Journal: Future oncology (London, England)

Published: October 27, 2025

Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model.

Journal: Cancers

Published: October 23, 2025

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings.

Journal: Health affairs scholar

Published: October 21, 2025

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.

Journal: Cancer heterogeneity and plasticity

Published: October 17, 2025

Filters

Senescence-Primed Ferroptosis Enabled by a Metal-Organic Framework Nanoplatform for Enhanced Cancer Therapy.

Senescence-Primed Ferroptosis Enabled by a Metal-Organic Framework Nanoplatform for Enhanced Cancer Therapy.

Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.

Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: analysis from a Medicare perspective.

Selective CDK6 Degradation via the KLHDC2 E3 Ubiquitin Ligase.

Selective CDK6 Degradation via the KLHDC2 E3 Ubiquitin Ligase.

Redox-responsive palbociclib-loaded self-assembled protein nanoparticles in breast cancer therapy-quality by design approach and efficacy assessment in 2D and 3D in vitro culture systems.

Redox-responsive palbociclib-loaded self-assembled protein nanoparticles in breast cancer therapy-quality by design approach and efficacy assessment in 2D and 3D in vitro culture systems.

Glycogen-Linked TPGS Nanomicelles for Hypoxia-Responsive PD-L1 Targeting and Molecular Imaging of Breast Tumor.

Glycogen-Linked TPGS Nanomicelles for Hypoxia-Responsive PD-L1 Targeting and Molecular Imaging of Breast Tumor.

Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.

Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis.

Cost-effectiveness analysis of ribociclib versus palbociclib as a first line therapy in HR+/HER2- advanced breast cancer: evidence from the Chilean Public Health system.

Cost-effectiveness analysis of ribociclib versus palbociclib as a first line therapy in HR+/HER2- advanced breast cancer: evidence from the Chilean Public Health system.

How to prevent and treat cardiovascular diseases in people living with breast cancer? Recent advances.

How to prevent and treat cardiovascular diseases in people living with breast cancer? Recent advances.

Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS.

Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS.

Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model.

Niclosamide and Palbociclib Act Synergistically to Reduce Cholangiocarcinoma Cell Viability In Vitro and Inhibit Tumour Growth in a Mouse Model.

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings.

The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings.

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.

Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response.